BOARD OF DIRECTORS
Tehila Ben Moshe, Ph.D.
Co-Founder, Chairperson & Chief Executive Officer
Tehila is the Co-Founder of Biond. She has served as Biond’s CEO and Board of Directors chairperson since the company’s inception. Tehila brings over a decade of scientific excellence and entrepreneurial leadership in biotech and pharma, combined with proven leadership skills and business acumen. Prior to founding Biond, Tehila was the CEO of cCAM Biotherapeutics and led the immuno-oncology company from launch through drug discovery and development and early stage clinical trials. The company was subsequently acquired by Merck (MSD) in 2015. cCAM was one of the first Israeli biotech companies to be acquired by a top pharma based on pre-clinical data, generating 10X return to investors in less than 3 years. Prior to her entrepreneurial career, Tehila led R&D projects at Protalix Biotherapeutics (NYSE/TASE: PLX) driving the development of ‘Bio-Better’ proteins from early stage up to clinic trials. Tehila holds a Ph.D. in Biochemistry from the Weizmann Institute where she studied immune signaling pathways in health and disease. She holds undergraduate degrees in Neuroimmunology and Biotechnology from Bar-Ilan University and the Hebrew University, respectively. She is the author of multiple patents and peer-reviewed scientific publications.
Ori Shilo, MBA
Co-Founder & Chief Financial Officer
Ori is the Co-Founder of Biond. He serves as the company’s CFO and a member of its Board of Directors since inception. Prior to launching Biond, Ori was Co-Founder, CFO & Deputy CEO and Director at RedHill Biopharma (NASDAQ: RDHL), a late stage drug development company. During his time at RedHill he led the company’s IPO in the Tel-Aviv Stock Exchange and its dual listing on NASDAQ including several private and public financing rounds totaling over $100 million as well as overseeing two phase 3 and three phase 2 trials. Prior to RedHill, Ori was partner in ProSeed Capital Holding CVA, a Belgium-based boutique investment firm, responsible for investments and banking activities in Israel. Ori has over 20 year of experience in investment banking and consultancy for the pharma/biotech field and as a Co-Founder of pharma/biotech companies.
Ronit Bendori, Ph.D.
General partner at Evergreen
Ronit has served as a member of our Board of Directors since 2017. Ronit is a general partner at Evergreen, focuses on investments in the healthcare sector. Since 2014 she is also an early stage private investor. Before joining Evergreen, Ronit served as Vice President of Pharmos Ltd. (NASDAQ: PARS). Prior to that Ronit held senior positions at InterPharm Ltd. (Israel) and Ares-Serono (Switzerland). Ronit is a member of the board of trustees of the Academic College of Tel Aviv-Yaffo. She has taught industrial aspects of BioMed entrepreneurship in the Weizmann Institute and the Hebrew University. Ronit holds a PhD in molecular and cellular biology from the Weizmann Institute of Science.
Yuval Cabilly, Ph.D.
Co-founder and managing Partner, Israel Biotech Fund
Yuval has served as a member of our Board of Directors since 2021. He is the co-founder and Managing Partner of Israel Biotech Fund, a venture capital fund investing in exceptional Israeli pharmaceutical companies. Yuval serves on the Board of Directors of Pharma Two B and Tamarix. He is also the co-founder and a Board Member of 8400 – The Health Network. Dr. Cabilly received his PhD in molecular cell biology from the Tel Aviv University. His research focused on neurodegenerative diseases.
Tomer Goldberg, MBA, LL.B.
VP, Managing Director, Harel Insurance & Finance
Tomer has served as a member of our Board of Directors since 2021. He joined Harel in 2021 to lead the technology investment practice. Before that, Tomer was part of Cisco Investments, focusing on the full range of strategic initiatives, including acquisitions and investments, that Cisco pursues in Israel. Prior to Cisco, Tomer was at Audible, an Amazon company, as a Senior Product Manager focused on web and mobile apps, and before that, Tomer was at Deloitte Consulting working with Technology, Media and Telecom clients. Tomer began his career in the Israeli Defense Forces’ UAV (Unmanned Aerial Vehicles) unit as a pilot and officer. Tomer holds an MBA from Columbia University’s Business School and an LLB from the University of Haifa, Israel.
Jerome B. Zeldis, M.D., Ph.D.
Jerome was appointed to our Board of Directors in June 2020. He is Executive Chair of ViralClear Pharmaceuticals, Inc. and previously served as Chief Medical Officer and President of Clinical Research, Medical Affairs, Drug Safety, Quality, and Regulatory at Sorrento Therapeutics, Inc. Prior to Sorrento he had a nearly 20-year career at Celgene during which he was instrumental in growing Celgene into one of the leading global biopharmaceutical companies. At Celgene, Jerome held the position of Chief Medical Officer and Chief Executive Officer of Celgene Global Health. In that capacity, Jerome oversaw multiple clinical trials using Celgene’s molecules. Jerome trained in Internal Medicine at the UCLA Center for the Health Sciences and Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. He was Assistant Professor of Medicine at the Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School and Professor of Clinical Medicine at the Robert Wood Johnson Medical School. He has published 123 peer reviewed articles and 44 US patents.